Cargando…
Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy
Glioblastoma multiforme (GBM) is the deadliest and the most heterogeneous brain cancer. The median survival time of GBM patients is approximately 8 to 15 months after initial diagnosis. GBM development is determined by numerous signaling pathways and is considered one of the most challenging and com...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138518/ https://www.ncbi.nlm.nih.gov/pubmed/35625738 http://dx.doi.org/10.3390/biomedicines10051001 |
_version_ | 1784714642152488960 |
---|---|
author | Pająk, Beata |
author_facet | Pająk, Beata |
author_sort | Pająk, Beata |
collection | PubMed |
description | Glioblastoma multiforme (GBM) is the deadliest and the most heterogeneous brain cancer. The median survival time of GBM patients is approximately 8 to 15 months after initial diagnosis. GBM development is determined by numerous signaling pathways and is considered one of the most challenging and complicated-to-treat cancer types. Standard GBM therapy consist of surgery followed by radiotherapy or chemotherapy, and combined treatment. Current standard of care (SOC) does not offer a significant chance for GBM patients to combat cancer, and the selection of available drugs is limited. For almost 20 years, there has been only one drug, Temozolomide (TMZ), approved as a first-line GBM treatment. Due to the limited efficacy of TMZ and the high rate of resistant patients, the implementation of new chemotherapeutics is highly desired. However, due to the unique properties of GBM, many challenges still need to be overcome before reaching a ‘breakthrough’. This review article describes the most recent compounds introduced into clinical trials as drug candidates for GBM chemotherapy. |
format | Online Article Text |
id | pubmed-9138518 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91385182022-05-28 Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy Pająk, Beata Biomedicines Review Glioblastoma multiforme (GBM) is the deadliest and the most heterogeneous brain cancer. The median survival time of GBM patients is approximately 8 to 15 months after initial diagnosis. GBM development is determined by numerous signaling pathways and is considered one of the most challenging and complicated-to-treat cancer types. Standard GBM therapy consist of surgery followed by radiotherapy or chemotherapy, and combined treatment. Current standard of care (SOC) does not offer a significant chance for GBM patients to combat cancer, and the selection of available drugs is limited. For almost 20 years, there has been only one drug, Temozolomide (TMZ), approved as a first-line GBM treatment. Due to the limited efficacy of TMZ and the high rate of resistant patients, the implementation of new chemotherapeutics is highly desired. However, due to the unique properties of GBM, many challenges still need to be overcome before reaching a ‘breakthrough’. This review article describes the most recent compounds introduced into clinical trials as drug candidates for GBM chemotherapy. MDPI 2022-04-26 /pmc/articles/PMC9138518/ /pubmed/35625738 http://dx.doi.org/10.3390/biomedicines10051001 Text en © 2022 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pająk, Beata Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy |
title | Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy |
title_full | Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy |
title_fullStr | Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy |
title_full_unstemmed | Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy |
title_short | Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy |
title_sort | looking for the holy grail—drug candidates for glioblastoma multiforme chemotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138518/ https://www.ncbi.nlm.nih.gov/pubmed/35625738 http://dx.doi.org/10.3390/biomedicines10051001 |
work_keys_str_mv | AT pajakbeata lookingfortheholygraildrugcandidatesforglioblastomamultiformechemotherapy |